Climb Bio (NASDAQ:CLYM) Posts Earnings Results, Beats Estimates By $0.02 EPS

Climb Bio (NASDAQ:CLYM - Get Free Report) released its quarterly earnings results on Tuesday. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.02, Zacks reports.

Climb Bio Stock Performance

Shares of NASDAQ:CLYM traded up $0.01 during mid-day trading on Friday, reaching $1.28. 115,261 shares of the company were exchanged, compared to its average volume of 367,710. Climb Bio has a 1 year low of $1.20 and a 1 year high of $11.55. The company has a 50-day moving average price of $1.54. The company has a market cap of $86.37 million, a price-to-earnings ratio of -0.60 and a beta of -0.19.

Wall Street Analysts Forecast Growth

CLYM has been the topic of a number of research analyst reports. Leerink Partnrs upgraded Climb Bio to a "strong-buy" rating in a research report on Monday, December 2nd. Leerink Partners began coverage on shares of Climb Bio in a report on Monday, December 2nd. They issued an "outperform" rating and a $10.00 price objective on the stock.

About Climb Bio

Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases.